CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
about
Targeting the CCL2-CCR2 signaling axis in cancer metastasisPrognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical reviewMonocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-κB ActivityData report on inflammatory C-C chemokines among insulin-using women with diabetes mellitus and breast cancer.Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.-2518 A/G MCP-1 but not -403 G/A RANTES gene polymorphism is associated with enhanced risk of basal cell carcinoma.Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes.Insulin secretagogue use and circulating inflammatory C-C chemokine levels in breast cancer patients.Inflammation and prostate cancer: friends or foe?Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer.CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro.Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model.Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients.sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients.Platelet to lymphocyte ratio plays an important role in prostate cancer's diagnosis and prognosis.Association of mast cell infiltration with gastric cancer progression.
P2860
Q26765184-1EA6C4AD-EFB3-49DA-A0CE-0433974519B0Q28073742-825FE085-0D2F-4C43-91B1-90EAD83760D9Q35994680-EEFA66EA-2438-4FFB-A0DD-F09AFD4C566AQ36306957-9E6AEBC2-AE48-4047-8A13-48C5128C8AF6Q36946815-63F73AD6-200D-4E0F-B771-0AF99029CBDEQ37416312-ED835750-95B6-4B59-B727-FCB52E0C9366Q37597723-DEB6F862-8910-44B9-A466-3F5F97E96614Q37672586-14724E44-58E0-4765-8331-F9CCBC95B44DQ38383521-D05F4446-B162-46AB-9FD2-A4621ACEE5E7Q38844891-62630D38-1DD7-4C84-B483-7D871BB6A024Q38960744-F344FF99-7754-4FA4-891C-1056F44D0E2AQ39985240-03EF1F67-DDAB-4CA5-85A2-3CC70EED4184Q41388484-70C82DA8-9482-4FAE-9145-51479C0104CFQ41450346-51496B39-871F-42D6-8EBE-4300B899BBE6Q43183253-CC39E125-60D3-452E-B818-86FA2A0ACC05Q49666838-B2D6EBE9-D049-41CB-80DE-369656FD6C8F
P2860
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
@en
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
@nl
type
label
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
@en
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
@nl
prefLabel
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
@en
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
@nl
P2093
P2860
P356
P1476
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
@en
P2093
Ana Maria Waaga-Gasser
Anika Noack
Axel Haferkamp
David Schilling
Elsie Oppermann
Georg Bartsch
Hendrik Borgmann
Igor Tsaur
Jasmina Makarevic
Kilian M Gust
P2860
P304
P356
10.4143/CRT.2014.015
P577
2014-10-13T00:00:00Z